CN101497605A - Benzimidazole derivative containing alkoxy substituted pyridine - Google Patents

Benzimidazole derivative containing alkoxy substituted pyridine Download PDF

Info

Publication number
CN101497605A
CN101497605A CNA2008100141199A CN200810014119A CN101497605A CN 101497605 A CN101497605 A CN 101497605A CN A2008100141199 A CNA2008100141199 A CN A2008100141199A CN 200810014119 A CN200810014119 A CN 200810014119A CN 101497605 A CN101497605 A CN 101497605A
Authority
CN
China
Prior art keywords
methyl
group
represent hydrogen
hydrogen atom
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2008100141199A
Other languages
Chinese (zh)
Other versions
CN101497605B (en
Inventor
黄振华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Xuanzhu Pharma Co Ltd
Original Assignee
Shandong Xuanzhu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Xuanzhu Pharma Co Ltd filed Critical Shandong Xuanzhu Pharma Co Ltd
Priority to CN200810014119A priority Critical patent/CN101497605B/en
Publication of CN101497605A publication Critical patent/CN101497605A/en
Application granted granted Critical
Publication of CN101497605B publication Critical patent/CN101497605B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medicines, and in particular relates to a benzimidazole derivative containing pyridine substituted by alkoxy as well as pharmaceutically acceptable salts or isomers thereof shown in a general formula (I), wherein R<1>, R<2>, R<3>, R<4>, R<5> and n are defined as the specification. The invention also relates to a method for preparing the compounds and a pharmaceutical composition containing the compounds, and application of the compounds to preparing the medicines for treating and/or preventing peptic ulcer.

Description

The benzimidizole derivatives that contains the pyridine of alkoxy replacement
1, technical field
The invention belongs to medical technical field, be specifically related to contain benzimidizole derivatives, its pharmacy acceptable salt and the isomer thereof of the pyridine that alkoxy replaces, the preparation method of these compounds, the pharmaceutical composition that contains these compounds, and these compounds treat and/or prevent application in the medicine of peptide ulceration in preparation.
2, background technology
Digestive system is one of common frdquently encountered disease, and wherein the Peptic Ulcers sickness rate accounts for 10%～12% of total population.Initial methods of treatment mainly is to use the purpose that reaches mitigation symptoms in the antacid (as sodium bicarbonate, aluminium hydroxide etc.) with hydrochloric acid in gastric juice.After the seventies in 20th century, along with H 2The discovery of gastric acid secretion inhibitor such as receptor blocking agent, proton pump inhibitor, the New Times of having started treatment of peptic ulcer, these medicines have instant effect, characteristics that ulcer healing rate is high, reduce the surgical operation rate greatly.
Omeprazole is the proton pump inhibitor of first listing, relies on its unique curative effect, in the competition of anti-ulcer medicament market and H2 receptor blocking agent, progressively obtains windward, 1996, becomes the first in the world best-selling drugs, and occupies the first place for successive years.Behind omeprazole, new proton pump inhibitor constantly comes out, lansoprazole, pantoprazole, rabeprazole and the esomeprazole in addition of listing successively.Yet, this class drug effect time is slow, drug effect is strong inadequately, need take medicine several times (after being several days) just can obtain the maximum sour effect that presses down, and differ to stablize in 24 hours surely and press down acid, take medicine and eating time all may influence drug effect and pharmacokinetic parameter, the pharmacokinetics individual difference is big, interacts obviously with other drug.
Therefore it is rapid-action to develop a class, but sour effective, and energy continued to press down sour in 24 hours, and individual difference is little, and the proton pump inhibitor few with the other medicines interaction becomes market demand.
3, summary of the invention
The inventor provides a class proton pump inhibitor through a large amount of experimental studies, has good gastric acid inhibitory excretory effect.
Technical scheme of the present invention is as follows:
The invention provides the compound shown in the general formula (I), its pharmacy acceptable salt and isomer thereof:
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group;
R 2, R 3Independently represent hydrogen atom, C respectively 1-6Alkyl or C 1-6Alkoxyl group;
R 4, R 5Independently represent hydrogen atom respectively, halogen atom or the C that is not substituted or is replaced by halogen atom 1-6Alkyl or C 1-6Alkoxyl group;
N represents 1～6 integer.
Preferred compound is:
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group, described carboxyl-protecting group is selected from: methyl, methoxymethyl, first thiomethyl, benzyloxymethyl, phenacyl, ethyl, the tertiary butyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R 2, R 3Independently represent hydrogen atom respectively, methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, methoxyl group, oxyethyl group, positive propoxy, isopropoxy or butoxy;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, chlorine atom, bromine atoms, methyl, ethyl, propyl group, sec.-propyl, methoxyl group, oxyethyl group, positive propoxy, isopropoxy, methyl fluoride, difluoromethyl, trifluoromethyl, fluorine methoxyl group, difluoro-methoxy, trifluoromethoxy or 1,1-two fluoro-oxyethyl groups;
N represents 1,2,3 or 5.
Further preferred compound is:
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group, described carboxyl-protecting group is selected from: methyl, the tertiary butyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R 2, R 3Independently represent hydrogen atom respectively, methyl, ethyl, propyl group, methoxyl group, oxyethyl group or propoxy-;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, chlorine atom, bromine atoms, methyl, ethyl, methoxyl group, oxyethyl group, difluoromethyl, trifluoromethyl, difluoro-methoxy or trifluoromethoxy;
N represents 1,2,3 or 4.
Further preferred compound is:
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group, described carboxyl-protecting group is selected from: methyl, the tertiary butyl, to nitrobenzyl, allyl group or benzyl;
R 2, R 3Independently represent hydrogen atom, methyl, ethyl, methoxy or ethoxy respectively;
R 4, R 5Independently represent hydrogen atom, methyl, ethyl, methoxy or ethoxy respectively;
N represents 1,2,3 or 4.
" halogen atom " of the present invention is fluorine atom, chlorine atom, bromine atoms or iodine atom.
" C of the present invention 1-6Alkyl " be methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl etc.
" C of the present invention 1-6Alkoxyl group " be methoxyl group, oxyethyl group, positive propoxy, isopropoxy, n-butoxy, tert.-butoxy, n-pentyloxy, positive hexyloxy etc.
" carboxyl-protecting group " mentioned above refers to that routine is used for the blocking group of substituted carboxylic acid character.This examples of groups comprises: methoxymethyl, the first thiomethyl, THP trtrahydropyranyl, tetrahydrofuran base, the methoxyethyl methyl, benzyloxymethyl, phenacyl, to bromobenzene formyl methyl, the Alpha-Methyl phenacyl, to the methoxybenzoyl methyl, the diacyl methyl, the N-phthalimidomethyl, ethyl, 2,2,2-three chloroethyls, the 2-halogenated ethyl, ω-chloro alkyl, 2-(trimethyl silyl) ethyl, 2-methylmercaptoethyl, 2-(p-nitrophenyl sulfenyl) ethyl, 2-(to the toluene sulfenyl) ethyl, 1-methyl isophthalic acid-styroyl, the tertiary butyl, cyclopentyl, cyclohexyl, two (ortho-nitrophenyl base) methyl, 9-fluorenyl methyl, 2-(9, the 10-dioxo) fluorenyl methyl, 5-hexichol sulfenyl, 2,4, the 6-trimethyl benzyl, to bromobenzyl, adjacent nitrobenzyl, to nitrobenzyl, to methoxy-benzyl, piperonyl, the 4-picolyl, trimethyl silyl, triethylsilyl, t-butyldimethylsilyl, the sec.-propyl dimetylsilyl, the phenyl dimetylsilyl, the S-tertiary butyl, the S-phenyl, the S-2-pyridyl, N-hydroxy piperidine base, N-hydroxyl succinimido, N-hydroxyl phthaloyl imino, N-hydroxybenzotriazole base, O-acyl group oxime, 2,4-dinitrobenzene sulfenyl, 2-alkyl-1, the 3-oxazoline, 4-alkyl-5-oxo-1, the 3-oxazolidine, 5-alkyl-4-oxo-1, the 3-diox, the triethyl stannane, tri-n-butyl stannane; N, N '-di-isopropyl hydrazides.
Further preferred compound is as follows:
Chemical name: 4-carboxyl-2-[[4-(3-methoxy propoxy)-3-methyl-pyridine-2-yl] methylsulfinyl]-benzoglyoxaline, be called for short compound 1.Structural formula:
The present invention also provides the preparation method of above-claimed cpd, but is not limited only to following method,
Reactions steps:
The preparation of step 1 intermediate 1
Raw material 1 is dropped in the reaction flask, add ethyl acetate, add oxyethyl group sulphur ortho acid potassium then, reflux, reaction is finished, be chilled to room temperature, reaction solution is poured in the frozen water, after stirring, regulate pH, separate out solid with hydrochloric acid, filter, be washed to neutrality, filter cake vacuum-drying gets intermediate 1.
The preparation of step 2 intermediate 2
Adding raw material 2 in the exsiccant reaction flask, raw material 3, potassium carbonate powder, heated and stirred refluxes, and stopped reaction is chilled to room temperature, filters, and filtrate decompression concentrates and reclaims excessive raw material 3, gets intermediate 2.
The preparation of step 3 intermediate 3
In the exsiccant reaction flask, add intermediate 2, diacetyl oxide, the intensification stirring reaction removes diacetyl oxide under reduced pressure, hydro-oxidation sodium solution in residue, stirring reaction use chloroform extraction, dry concentrated intermediate 3.
The preparation of step 4 intermediate 4
Add methylene dichloride in intermediate 3, cool off, be added dropwise to sulfur oxychloride, drip off the back and stir, remove methylene dichloride and sulfur oxychloride under reduced pressure, adding yellow soda ash is molten in debris then, chloroform extraction, and combining extraction liquid, drying concentrates, and gets intermediate 4.
The preparation of step 5 intermediate 5
In intermediate 4, add ethanol, intermediate 1, sodium hydroxide, the intensification stirring reaction removes ethanol under reduced pressure, and the chloroform extraction drying concentrates, and ethyl alcohol recrystallization gets intermediate 5.
The preparation of step 6 The compounds of this invention
Add intermediate 5 in the reaction flask, methylene dichloride stirs cooling down, adds raw material 4 in batches, adds the back stirring reaction, add triethylamine, stir the back and heat up, add sodium carbonate solution, stir layering, water dichloromethane extraction, extraction liquid merge, and drying concentrates, filter crude product.Crude product is added dehydrated alcohol, and heating for dissolving is filtered, and filtrate adds diethyl ether, and precipitation occurs, filters, and gets The compounds of this invention.
Reaction equation:
Figure A200810014119D00071
R in the above reaction equation 1, R 2, R 3, R 4, R 5With n as mentioned before.
The The compounds of this invention pharmacy acceptable salt does not have special restriction, and example comprises inorganic acid addition salt, example hydrochloric acid salt, vitriol, nitrate, phosphoric acid salt, hydrobromate and hydriodate; Organic acid addition salt is as formate, acetate, propionic salt, oxalate, malonate, succinate, maleate, fumarate, lactic acid salt, malate, Citrate trianion, tartrate, mesylate, esilate, benzene sulfonate, tosylate and a tetrafluoro borate; Amino acid salts is as arginic acid salt, aspartate and glutaminate; Metal-salt is as lithium salts, sodium salt, sylvite, calcium salt, magnesium salts and bismuth salt.Be preferably: hydrochloride, hydrobromate, hydriodate, acetate, maleate, fumarate, lactic acid salt, malate, Citrate trianion, tartrate, mesylate, benzene sulfonate, arginic acid salt, glutaminate, sodium salt, sylvite, calcium salt, magnesium salts.
The compounds of this invention can also exist with enantiomeric forms, and when a key was represented with a wedge, this showed that this key will come out from paper on three-dimensional, and when a key was shade, this showed that this key will return in the paper on three-dimensional.Formula (I) compound has three-dimensional center, and these isomer are also included within the scope of the present invention.
The compounds of this invention also can with hydrate or form exist, these hydrates should be also included within the scope of the present invention.
Proton pump inhibitor (PPIs) can gastric acid inhibitory secretion treatment peptide ulceration, its mechanism be by with near the stomach H that is positioned at the parietal cell secretory tubyle acid space +/ K +Serine molecule on the-ATP enzyme is converted into the active amide based compound earlier in conjunction with playing a role in the sour environment of secretory tubyle, present the dose-dependent inhibition basis then and stimulate the back gastric acid secretion.
A large amount of studies have shown that, anti-Hp (Hp) infects and the generation and the recurrence of peptide ulceration have close getting in touch, and it is particularly important therefore to eradicate Hp in treatment ulcer.Proton pump inhibitor has the effect that suppresses or kill Hp, show two aspects: (1) directly suppresses Hp, its mechanism is PPIs increased activity in sour environment, and penetrable rete malpighii combines with the urease on Hp top layer, suppresses urease activity and reaches the Hp effect that suppresses; (2) PPIs can act synergistically with antimicrobial drug, many antimicrobial drugs have a very strong anti-Hp effect external, but it is not acidproof, easily degraded in gastric juice, can not play one's part to the full, raise with stomach pH behind the PPIs, bring into play anti-Hp effect for antimicrobial drug environment preferably is provided, make acid nonfast antimicrobial drug can bring into play maximum bactericidal effect.
The compounds of this invention is a proton pump inhibitor, the invention still further relates to The compounds of this invention or its pharmacy acceptable salt inhibition Mammals and people's gastric acid secretion, prevention and treatment Mammals and people's gastroenteritis disease and with the hydrochloric acid in gastric juice diseases associated, for example: gastritis, stomach ulcer, duodenal ulcer and backflow esophagitis.In addition, The compounds of this invention also can be used for other gastrointestinal illness that need utilize the gastric acid inhibitory secretion to treat, for example, be used for carrying out the patient of NSAID (non-steroidal anti-inflammatory drug) (NSAID) treatment, be used for the treatment of stomach gangrene (Gastrinomas) and acute upper stomach enterorrhagia.It also can be used for the patient that need give someone extra help, and be used for before the art and postoperative prevent that acid from absorbing and stress ulcer formation.The compounds of this invention also can be used to treat or prevent to comprise people's mammiferous inflammation, particularly relevant with N,O-Diacetylmuramidase disease.
The present invention is the claimed pharmaceutical composition that comprises The compounds of this invention, its pharmacy acceptable salt or its isomer and other activeconstituents further; the disease that is used for the treatment of or prevents peptide ulceration to be correlated with; described other active ingredient can be an antiseptic-germicide, particularly:
1) β-Nei Xiananleikangshengsu is as amoxycilline Trihydrate bp, Ampicillin Trihydrate, cefoxitin, cefaclor or Cefixime Micronized etc.;
2) Macrolide is as erythromycin or clarithromycin etc.;
3) tetracyclines is as tsiklomitsin or Vibravenos etc.;
4) aminoglycoside is as gentamicin, kantlex or amikacin etc.;
5) quinolones is as norfloxicin, Ciprofloxacin or enoxacin etc.;
6) other, as metronidazole, furadantin or paraxin etc.; Or
7) comprise the preparation of bismuth salt, as preparation of acid bismuth citrate, bismuth subsalicylate, Bismuth Subcarbonate, Vikaline or Bismuth Subgallate etc.
Can also be antacid, as aluminium hydroxide, magnesium hydroxide, magnesiumcarbonate and magnesium aluminate etc.;
Sedative drugs prescriptions as tranquilizer, comprises diamino heterocycle heptantriene etc.;
Spasmolytic is as bietamiverine and acamylophenine etc.;
Anticholinergic is as oxygen phenyl ring imines and phenol urea etc.;
Part narcotic is as tetracaine and PROCAINE HCL, PHARMA GRADE etc.;
Non-steroidal anti-inflammatory drug is as INDOMETHACIN, acetylsalicylic acid and naprosine etc.;
Steroid or nitrite remover are as xitix and thionamic acid etc.;
Other stomach ulcer medicines for treatment are as pirenzipine etc.;
The prostaglandin(PG) medicine, as 16,16-dimethyl PGE2 etc.;
Histamine H 2-antagonist, for example CIMETIDINE etc.
The present invention is the claimed pharmaceutical composition that comprises arbitrary compound recited above, its pharmacy acceptable salt or its isomer and one or more pharmaceutical carriers and/or thinner further; for clinically or pharmaceutically acceptable arbitrary formulation, be preferably oral preparations or injection.Wherein contain the compound 0.01～500mg shown in the general formula (I) of physiology significant quantity, be preferably 0.05～200mg, more preferably 0.1～120mg specifically comprises 0.1mg, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg, 80mg, 100mg, 120mg; Can be by 1～4 time arrangement every day, give described compound 1～2 time preferred every day.
Arbitrary compound of the present invention and pharmacy acceptable salt thereof can be oral or mode such as administered parenterally be applied to the patient who needs this treatment.
When being used for administered parenterally, can be made into injection.Injection means the intravital solution of confession injection, emulsion or the suspension that medicine is made and supplies to face with preceding preparation or be diluted to solution or the sterile preparation of the powder of suspension or strong solution that injection can be divided into injection liquid, injectable sterile powder and concentrated solution for injection.Injection liquid means that the confession that medicine is made is injected into sterile solution type injection liquid, emulsion-type injection liquid or the suspension type injection liquid of using in the body, can be used for intramuscularly, intravenous injection, intravenous drip etc.; Its specification has 1ml, 2ml, 5ml, 10ml, 20ml, 50ml, 100ml, 200ml, 250ml, 500ml etc., and wherein large volume (generally the being not less than 100ml) injection liquid of using for intravenous drip also claims intravenous infusion.Injectable sterile powder means that confession that medicine is made is faced with the suitable sterile solution of preceding usefulness and is mixed with settled solution or the evenly sterilized powder or the aseptic block of suspension, available suitable solvent for injection preparation back injection, also available intravenous infusion preparation posterior vein instils; Sterilized powder makes with solvent crystallization, spray-drying process or freeze-drying etc.Concentrated solution for injection means that confession that medicine is made faces the aseptic strong solution of using for intravenous drip with preceding dilution.
When making injection, can adopt the ordinary method production in the existing pharmacy field, optional use solvent or non-aqueous solvent.The most frequently used aqueous solvent is a water for injection, also available 0.9% sodium chloride solution or other suitable aqueous solution; Non-aqueous solvent commonly used is a vegetables oil, is mainly the injection soybean oil, and other also have the aqueous solution of ethanol, propylene glycol, polyoxyethylene glycol etc.During the preparation injection, can not add additives, also can add suitable additives, as osmotic pressure regulator, pH value conditioning agent, solubilizing agent, weighting agent, oxidation inhibitor, fungistat, emulsifying agent, suspending agent etc. according to the character of medicine.Osmotic pressure regulator commonly used comprises sodium-chlor, glucose, Repone K, magnesium chloride, calcium chloride, sorbyl alcohol etc., preferred sodium-chlor or glucose; PH value conditioning agent commonly used comprises acetic acid-sodium-acetate, lactic acid, Citric Acid-Sodium Citrate, sodium bicarbonate-yellow soda ash etc.; Solubilizing agent commonly used comprises Polysorbate 80, propylene glycol, Yelkin TTS, polyoxyethylenated castor oil etc.; Weighting agent commonly used comprises lactose, N.F,USP MANNITOL, sorbyl alcohol, dextran etc.; Oxidation inhibitor commonly used has S-WAT, sodium bisulfite, Sodium Pyrosulfite etc.; Fungistat commonly used is phenol, cresols, trichloro-butyl alcohol etc.Injection container commonly used has glass ampoule, vial, plastic ampoule, Plastic Bottle etc.
Be used for when oral, can be made into conventional solid preparation, as tablet, capsule, pill, granule etc.; Also can be made into oral liquid, as oral solution, oral suspensions, syrup etc.Tablet means disk shape or the special-shaped flaky solid preparation that medicine and the auxiliary materials and mixing compacting that suits form, based on oral ordinary tablet, other has lozenge, Sublingual tablet, mouth paster, chewable tablet, dispersible tablet, fuse, effervescent tablet, slow releasing tablet, controlled release tablet and enteric coated tablet etc.Capsule means medicine or is added with the auxiliary material filling in Capsules or be sealed in solid preparation in the soft capsule material, according to its dissolving and release characteristics, can be divided into hard capsule (being commonly referred to as capsule), soft capsule (capsule and pill), slow releasing capsule, controlled release capsule and enteric coated capsule etc.Pill means medicine and suitable auxiliary material uniform mixing, and the spherical or near-spherical solid preparation so that proper method is made comprises dripping pill, sugar-pill, piller etc.Granule means that medicine and suitable auxiliary material make the dried particles shape preparation with certain particle size, can be divided into soluble particles (being commonly referred to as particle), mix suspension grain, effervescent granule, enteric coated particles, slow-releasing granules and controlled release granule etc.Oral solution means that medicine dissolution makes for oral clarified liq preparation in suitable solvent.Oral suspensions means the insoluble solid pharmaceutical, is dispersed in the liquid medium, makes for oral suspension body preparation, also comprises dry suspensoid or dense suspension.Syrup means the dense aqueous sucrose solution that contains medicine.
When making oral preparations, can add suitable weighting agent, tackiness agent, disintegrating agent, lubricant etc.Weighting agent commonly used comprises starch, Icing Sugar, calcium phosphate, calcium sulfate two water things, dextrin, Microcrystalline Cellulose, lactose, pregelatinized Starch, N.F,USP MANNITOL etc.; Typical binders comprises Xylo-Mucine, PVP-K30, hydroxypropylcellulose, starch slurry, methylcellulose gum, ethyl cellulose, hypromellose, gelling starch etc.; Disintegrating agent commonly used comprises dry starch, polyvinylpolypyrrolidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose etc.; Conventional lubricants comprises Magnesium Stearate, talcum powder, sodium lauryl sulphate, micropowder silica gel etc.
The benzimidizole derivatives that contains the pyridine of alkoxy replacement of the present invention is compared with immediate prior art, has the following advantages:
1) The compounds of this invention can suppress Mammals and people's gastric acid secretion significantly, does not have potential toxic side effect, oral no GI irritation;
2) be lower than when being generally used for gastric acid inhibitory excretory effective dose when taking, then has provide protection to organs such as stomach, intestines, be meant prevention and treatment, refer in particular to the disease and the damage (for example stomach ulcer, duodenal ulcer and because the gastric irritation that hyperchlorhydria or medicament cause) of stomach inflammation gastroenteropathy;
3) The compounds of this invention has higher chemical stability, less by people CYP 2C 19Metabolism, and have low CYP 1A 2Inducibility;
4) the weak curative effect heteropole of The compounds of this invention between individuality is little, guarantees that the patient who accepts the same dose medicine can obtain suitable curative effect comparably;
5) The compounds of this invention has low passing through and induces CYP 1A family member enzyme and the danger of the drug interaction that causes and low cancer development danger are safe;
6) The compounds of this invention is rapid-action, strong drug action, and long half time presses down sour effect stability;
7) The compounds of this invention preparation technology is simple, and medicine purity height, yield height, steady quality are easy to carry out large-scale commercial production.
Below example is further set forth the beneficial effect of compound of the present invention by experiment, but this should be interpreted as that The compounds of this invention only has following beneficial effect.
1 couple of H of experimental example The compounds of this invention + -K + The inhibition of atpase activity
(1) H +-K +The preparation of adenosine triphosphatase
Improve one's methods (seeing Biochem.and Biophys-Acta, 464,313 (1977)) according to people such as Saccomani prepares H with the substrate body of gland of fresh pig stomach mucous membrane +-K +Adenosine triphosphatase.
(2) H +-K +The mensuration of atpase activity
In pH is 7.40 40mM Tri(Hydroxymethyl) Amino Methane Hydrochloride buffered soln, with the The compounds of this invention methanol solution and the H of different concns +-K +The protein of adenosine triphosphatase and 10 μ g/ml at 37 ℃ of following constant temperature culture 30min, adds 15mM Repone K after mixing then.Behind the 10min, add 3mM magnesium chloride and Triphosaden again and make the adenosine triphosphate enzyme reaction begin to carry out.After 10min, measure the amount of the inorganic phosphate that discharges according to the method (seeing Biochem.Biophys.Res.Com., 40,880 (1970)) of Yoda and Hokin.
(3) mensuration of inhibition effect: in above-mentioned experiment, to deduct the amount of the inorganic phosphate of behind the solution that adds a certain experimental compound, being emitted in the amount of the inorganic phosphate that only adds in the controlled trial to be emitted, the gained difference is represented with percentage ratio divided by the amount of the inorganic phosphate of controlled trial again, suppressed effect IC 50Expression.
Experimental result:
Table 1 couple H +-K +The restraining effect of atpase activity
Figure A200810014119D00121
Experimental result shows, 1 couple of H of The compounds of this invention +-K +The activity of adenosine triphosphatase has higher inhibition effect, and the security of height is arranged.So, can suppress the secretion of acid effectively, thereby can effectively treat and prevention of digestive tract ulcers.Compare more remarkable effect with rabeprazole.
4, embodiment
The embodiment of form is described in further detail foregoing of the present invention by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following examples.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.The auxiliary material of each formulation can be replaced with acceptable accessories in following examples, perhaps reduces, increases.
The preparation of embodiment 1 2-sulfydryl-4-methoxycarbonyl-benzoglyoxaline
With 2,3-diamino-methyl benzoate 10g (60mmol) drops in the reaction flask, adds ethyl acetate 200ml, adds oxyethyl group sulphur ortho acid potassium 12.8g (80mmol) then, at 80 ℃ of following reflux 4h.Reaction is finished, and is chilled to room temperature, and reaction solution is poured in the 200ml frozen water, after stirring, regulates pH3～4 with the hydrochloric acid of 4N, separates out solid, filters, and is washed to neutrality, and filter cake vacuum-drying gets product 9.1g, yield: 73.2%.
Embodiment 2 4-(3-methoxy propoxy)-2, the preparation of 3-dimethyl-N-pyridine oxide
The 4-(3-methoxy propoxy)-2 that in the exsiccant reaction flask, adds 16.8g (100mmol), 3-dimethyl-N-pyridine oxide, 1, ammediol monomethyl ether 100ml, potassium carbonate powder 20g, heated and stirred backflow 12h, stopped reaction is chilled to room temperature, filters, filtrate decompression concentrate to reclaim excessive 1, the ammediol monomethyl ether gets oily matter 4-(3-methoxy propoxy)-2,3-dimethyl-N-pyridine oxide 11.2g, yield: 53.2%, directly drop into to go on foot down and react.
The preparation of embodiment 3 4-(3-methoxy propoxy)-2-methylol-3-methyl-pyridine
The 4-(3-methoxy propoxy)-2 that in the exsiccant reaction flask, adds 21.1g (100mol), 3-dimethyl-N-pyridine oxide, the 200ml diacetyl oxide, be warmed up to 60 ℃ of stirring reactions 1 hour, remove diacetyl oxide under reduced pressure, in residue, add 2N sodium hydroxide solution 150ml, 40 ℃ of stirring reactions 4 hours, with chloroform (100ml * 3) extraction, dry concentrate oily matter 14.8g, yield 70.2%.
The preparation of embodiment 4 4-(3-methoxy propoxy)-2-chloromethyl-3-methyl-pyridine
In 4-(3-methoxy propoxy)-2-methylol-3-methyl-pyridine 16.9g (80mmol), add methylene dichloride 400ml, be as cold as 0 ℃, be added dropwise to sulfur oxychloride 15ml, drip off back stirring at room 1 hour, remove methylene dichloride and sulfur oxychloride under reduced pressure, in debris, add 10% sodium carbonate solution 90ml, chloroform extraction (100ml * 3), combining extraction liquid then, dry, concentrate, get product 16.7g, yield 91.1%.
Embodiment 5 4-methoxycarbonyl-2-[[4-(3-methoxy propoxy)-3-methyl-pyridine-2-yl] methyl sulphur]-system of benzoglyoxaline Be equipped with
In 4-(3-methoxy propoxy)-2-chloromethyl-3-methyl-pyridine 16.1g (70mmol), add ethanol 200ml, 2-sulfydryl-4-methoxycarbonyl-benzoglyoxaline 15.6g (75mmol), 2N sodium hydroxide 50ml, be warmed up to 70 ℃ of stirring reactions 1 hour, remove ethanol under reduced pressure, chloroform extraction (150ml * 3) drying, concentrate, ethyl alcohol recrystallization gets solid 14.6g, yield 52.1%.
Embodiment 6 4-methoxycarbonyl-2-[[4-(3-methoxy propoxy)-3-methyl-pyridine-2-yl] methylsulfinyl]-the benzo miaow The preparation of azoles
Add 4-methoxycarbonyl-2-[[4-(3-methoxy propoxy)-3-methyl-pyridine-2-yl in the reaction flask] methyl sulphur]-benzoglyoxaline 12.0g (30mmol), methylene dichloride 160ml, be as cold as-30 ℃ under stirring, under this temperature, add 5g (29mmol) metachloroperbenzoic acid in batches, added the back stirring reaction 2 hours, and added the 2ml triethylamine, stir and be warmed up to 0 ℃ after 30 minutes, add 5% sodium carbonate solution 200ml, stirring at room 1 hour, layering, water dichloromethane extraction (150ml * 2), extraction liquid merges, drying concentrates, filter crude product.Crude product is added the 100ml dehydrated alcohol, and heating for dissolving is filtered, and filtrate adds the 200ml ether, precipitation occurs, filters, and gets off-white color solids 11.3g, yield 90.6%.
Embodiment 7 4-carboxyl-2-[[4-(3-methoxy propoxy)-3-methyl-pyridine-2-yl] methylsulfinyl]-benzoglyoxaline Preparation
In reaction flask, add 4-methoxycarbonyl-2-[[4-(3-methoxy propoxy)-3-methyl-pyridine-2-yl] methylsulfinyl]-benzoglyoxaline 4.2g (10mmol), dehydrated alcohol 20ml, the 1N HCl of 10ml, heated and stirred backflow 2h.Reaction is finished, and removes solvent under reduced pressure, and residuum adds 20ml ethanol again, and heating for dissolving postcooling crystallization gets product 3.2g, yield: 78.5%.Molecular formula: C 19H 21N 3O 5S
Molecular weight: 403.45
Ultimate analysis: measured value: C, 56.34%; H, 5.46%; N, 10.21%; S, 8.18%
Calculated value: C, 56.56%; H, 5.25%; N, 10.42%; S, 7.95%
The preparation of embodiment 8 The compounds of this invention freeze-dried powders
1, prescription:
Prescription 1:
Figure A200810014119D00131
Prescription 2:
Figure A200810014119D00141
2, preparation technology: take by weighing supplementary material by prescription; There is the water for injection of dosing amount 80% to dissolve in N.F,USP MANNITOL, adds the EDTA-Na2 dissolving; Any one stirring and dissolving in compound 1 or derivatives thereof is complete, measures the pH value, regulates pH to proper range with hydrochloric acid and the sodium hydroxide of 1mol/L, add water for injection to full dose, add the gac of dosing amount 0.05%, 30 ℃ of insulated and stirred 20min, filtering decarbonization, with 0.45 μ m filtering with microporous membrane, the inspection of semifinished product, soup is with 0.22 μ m filtering with microporous membrane, check clarity, can, false add plug, freeze-drying, freeze-dry process is: 40mg;
Specification freeze-dry process :-40 ℃ of pre-freeze 3h ,-40～-5 ℃ of low-temperature distillation 15h ,-5～30 ℃ of dry 4h that heat up, 30 ℃ of high temperature drying 2.5h; Freeze-drying finishes, and lid is rolled in tamponade, packing, full inspection.
The preparation of embodiment 9 The compounds of this invention tablets
1, prescription:
Prescription 1:
Figure A200810014119D00142
Prescription 2:
Figure A200810014119D00143
2, preparation technology: raw material pulverizing is crossed 100 mesh sieves, and all the other auxiliary materials are crossed 100 mesh sieves respectively, and are standby; Take by weighing raw material and auxiliary material according to recipe quantity; With in compound 1 or derivatives thereof any one, Microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl methylcellulose mix granulation, adds Magnesium Stearate then, micropowder silica gel is lubricated, sampling, work in-process chemical examination; According to the definite sheet weight sheet of chemical examination; Finished product is examined entirely, the packing warehouse-in.
The capsular preparation of embodiment 10 The compounds of this invention
1, prescription:
Prescription 1:
Prescription 2:
Figure A200810014119D00152
2, preparation technology: raw material pulverizing is crossed 100 mesh sieves, and all the other auxiliary materials are crossed 100 mesh sieves respectively, and are standby; Take by weighing raw material and auxiliary material according to recipe quantity; With in compound 1 or derivatives thereof any one, Microcrystalline Cellulose, pregelatinized Starch, starch mix granulation, adds Magnesium Stearate then, micropowder silica gel is lubricated, sampling, work in-process chemical examination; The loading amount of determining according to chemical examination incapsulates; Finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 11 The compounds of this invention enteric coated tablet
1, prescription:
Prescription 1:
Prescription 2:
Figure A200810014119D00154
2, preparation technology:
Plain sheet preparation: main ingredient was pulverized 100 mesh sieves, took by weighing supplementary material by recipe quantity, with Microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl methylcellulose and main ingredient mix, and add water and make softwood in right amount, softwood is crossed 18 mesh sieves and is granulated, particle is at 60 ℃ of baking oven inner dryings, and drying finishes, and crosses the whole grain of 18 mesh sieves, add Magnesium Stearate and micropowder silica gel, mix, the inspection of semifinished product, trim plate is heavy, compressing tablet.Dressing: Opadry enteric coating powder adds the Virahol of recipe quantity and water stirring and evenly mixing, and to be prepared into coating liquid standby, gets plain sheet and put in the coating pan, and label is preheating to 40 ℃, begins to spray coating liquid.Coating pan rotating speed 25r/min, spray pressure 0.3Mpa-0.4Mpa, the label temperature is controlled at 30～40 ℃, dressing increase weight sheet heavy 7%, stop spraying, continue heating, be put in the pallet after treating to take out after the tablet drying and cool.

Claims (10)

1, the compound shown in the general formula (I), its pharmacy acceptable salt and isomer thereof:
Figure A200810014119C00021
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group;
R 2, R 3Independently represent hydrogen atom, C respectively 1-6Alkyl or C 1-6Alkoxyl group;
R 4, R 5Independently represent hydrogen atom respectively, halogen atom or the C that is not substituted or is replaced by halogen atom 1-6Alkyl or C 1-6Alkoxyl group;
N represents 1～6 integer.
2, compound as claimed in claim 1, its pharmacy acceptable salt and isomer thereof:
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group, described carboxyl-protecting group is selected from: methyl, methoxymethyl, first thiomethyl, benzyloxymethyl, phenacyl, ethyl, the tertiary butyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R 2, R 3Independently represent hydrogen atom respectively, methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, methoxyl group, oxyethyl group, positive propoxy, isopropoxy or butoxy;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, chlorine atom, bromine atoms, methyl, ethyl, propyl group, sec.-propyl, methoxyl group, oxyethyl group, positive propoxy, isopropoxy, methyl fluoride, difluoromethyl, trifluoromethyl, fluorine methoxyl group, difluoro-methoxy, trifluoromethoxy or 1,1-two fluoro-oxyethyl groups;
N represents 1,2,3 or 5.
3, compound as claimed in claim 2, its pharmacy acceptable salt and isomer thereof:
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group, described carboxyl-protecting group is selected from: methyl, the tertiary butyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R 2, R 3Independently represent hydrogen atom respectively, methyl, ethyl, propyl group, methoxyl group, oxyethyl group or propoxy-;
R 4, R 5Independently represent hydrogen atom respectively, fluorine atom, chlorine atom, bromine atoms, methyl, ethyl, methoxyl group, oxyethyl group, difluoromethyl, trifluoromethyl, difluoro-methoxy or trifluoromethoxy;
N represents 1,2,3 or 4.
4, compound as claimed in claim 3, its pharmacy acceptable salt and isomer thereof:
Wherein: R 1Represent hydrogen atom or carboxyl-protecting group, described carboxyl-protecting group is selected from: methyl, the tertiary butyl, to nitrobenzyl, allyl group or benzyl;
R 2, R 3Independently represent hydrogen atom, methyl, ethyl, methoxy or ethoxy respectively;
R 4, R 5Independently represent hydrogen atom, methyl, ethyl, methoxy or ethoxy respectively;
N represents 1,2,3 or 4.
5, compound as claimed in claim 4, for
4-carboxyl-2-[[4-(3-methoxy propoxy)-3-methyl-pyridine-2-yl] methylsulfinyl]-benzoglyoxaline, its pharmacy acceptable salt and isomer thereof.
6, as the described compound of the arbitrary claim of claim 1～5, it will learn acceptable salt is inorganic acid addition salt, organic acid addition salt and metal-salt, comprise hydrochloride, hydrobromate, hydriodate, acetate, maleate, fumarate, lactic acid salt, malate, Citrate trianion, tartrate, mesylate, benzene sulfonate, arginic acid salt, glutaminate, sodium salt, sylvite, calcium salt, magnesium salts.
7, as the pharmaceutical composition of the described compound of the arbitrary claim of claim 1～5, its pharmacy acceptable salt or its isomer and one or more pharmaceutical carriers and/or thinner, be pharmaceutically acceptable arbitrary formulation.
8, pharmaceutical composition as claimed in claim 7 contains the described compound of the arbitrary claim of claim 1～5, its pharmacy acceptable salt or its isomer 0.01～500mg as essential activeconstituents.
9, the pharmaceutical composition that comprises the described compound of the arbitrary claim of claim 1～5, its pharmacy acceptable salt or its isomer and other activeconstituentss.
10, as the described compound of the arbitrary claim of claim 1～5, its pharmacy acceptable salt and isomer thereof in the application that is used for preparing the medicine that treats and/or prevents peptide ulceration.
CN200810014119A 2008-01-30 2008-01-30 Benzimidazole derivative containing alkoxy substituted pyridine Active CN101497605B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200810014119A CN101497605B (en) 2008-01-30 2008-01-30 Benzimidazole derivative containing alkoxy substituted pyridine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200810014119A CN101497605B (en) 2008-01-30 2008-01-30 Benzimidazole derivative containing alkoxy substituted pyridine

Publications (2)

Publication Number Publication Date
CN101497605A true CN101497605A (en) 2009-08-05
CN101497605B CN101497605B (en) 2012-08-29

Family

ID=40944894

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200810014119A Active CN101497605B (en) 2008-01-30 2008-01-30 Benzimidazole derivative containing alkoxy substituted pyridine

Country Status (1)

Country Link
CN (1) CN101497605B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
WO2003082854A1 (en) * 2002-03-29 2003-10-09 Zeria Pharmaceutical Co., Ltd. 1-n-aminobenzimidazole derivatives

Also Published As

Publication number Publication date
CN101497605B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
KR100501034B1 (en) Celecoxib composition
CN110054624B (en) Berberine hydrochloride and caffeic acid eutectic compound, preparation method, composition and application thereof
CN112851666B (en) Apixaban and quercetin eutectic, preparation method, composition and application thereof
CN101412690A (en) Medicinal acid addition salt of silodosin, and preparation and medicament use thereof
CN102712649B (en) Benzimidazole derivatives and pharmaceutical compositions and uses thereof
TW201831191A (en) Novel boric acid derivative and pharmaceutical composition using same
CN103087042B (en) Salts of sitafloxacin and pharmaceutical purposes thereof
CN115124420B (en) Rhein and matrine eutectic hydrate, preparation method, composition and application thereof
CN101492452B (en) Sulfhydryl benzimidazole derivative containing dioxepane-pyridine
CN101492461B (en) Benzimidazole derivative containing alkoxyl oxygen alkyl ethyl substituted pyridine-tetrahydrochysene isoxazole
CN101497605B (en) Benzimidazole derivative containing alkoxy substituted pyridine
CN101497616B (en) Imidazopyridine compound containing aminoxy substituted pyridine
CN101492462B (en) Benzimidazole derivative containing isoxazole-pyridine
CN101492464B (en) Sulfhydryl imidazopyridine derivative containing dioxepane-pyridine
CN101492460B (en) Benzimidazole derivative containing alkoxyl oxygen alkyl substituted pyridine-tetrahydrochysene isoxazole
CN101492446A (en) Novel pyridine-imidazole derivative
CN101497604B (en) Benzimidazole derivative containing alkoxy acetamide substituted pyridine
CN101497603B (en) Benzimidazole derivative containing alkoxy alkanamine oxyl substituted pyridine
CN101497623B (en) Compound containing imidazopyridine
CN101492459B (en) Compound containing alcoxyl acetyl dihydrogen isoxazole-pyridine
CN101497622B (en) Pyridine methyl sulfinyl imidazopyridine derivative
CN101492463B (en) Imidazopyridine derivative containing dioxane-pyridine
KR100192534B1 (en) Agent for increasing somatostatin or for inhibiting decrease of somatostatin
CN101492454A (en) Benzimidazole derivative containing alkoxyl oxygen ethyl substituted pyridine-tetrahydrofuran
CN101492453A (en) Sulfhydryl benzimidazole derivative containing dihydrofuran-pyridine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant